Data suggest gene, cell therapy trial initiations in Europe lag behind North America here’s why – Endpoints News

No new drug has been approved for Alzheimers since 2003, and researchers endeavoring to change that have been greeted with a graveyard of failed therapies. So when Chinese regulators waved a treatment developed by an obscure biotech through to the market albeit a conditional approval contingent upon confirmatory data it makes sense that scientists who woke up to the news were more in doubt than in awe.

While several prominent Alzheimers experts threw their weight behind the seaweed-derived therapy, oligomannate (GV-971), others contacted by Endpoints News were much more skeptical. As Green Valley Pharma has yet to release full data of the single Phase III trial on which the decision was based, most are taking a wait-and-see stance while the company prepares to launch a second, global trial in early 2020.

Among the deluge of questions surrounding the surprise approval, two seem particularly crucial: Did Green Valley offer enough credible evidence to warrant an OK? And did the drug really work as the biotech claimed?

Unlock this article along with other benefits by subscribing to one of our paid plans.

SUBSCRIBE SIGN IN

Read the original here:
Data suggest gene, cell therapy trial initiations in Europe lag behind North America here's why - Endpoints News